Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade A 53.72 2.68% 1.40
ACAD closed up 2.68 percent on Tuesday, July 14, 2020, on 50 percent of normal volume.
Earnings due: Jul 29
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical ACAD trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.68%
Down 3 Days in a Row Weakness 2.68%
Down 4 Days in a Row Weakness 2.68%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.12%
NR7 Range Contraction -3.12%
Upper Bollinger Band Walk Strength -3.12%
Overbought Stochastic Strength -3.12%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Biopharmaceutical Health Pharmaceutical Industry Medication Chemical Compounds Alzheimer's Disease Parkinson's Disease Schizophrenia Neurological Disorders Glaucoma Chronic Pain Treatment Of Parkinson's Disease Treatment Of Alzheimer's Disease Treatment Of Glaucoma Muscarinic Agonist

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 58.72
52 Week Low 21.56
Average Volume 1,625,019
200-Day Moving Average 44.61
50-Day Moving Average 49.91
20-Day Moving Average 51.71
10-Day Moving Average 53.50
Average True Range 2.56
ADX 20.07
+DI 27.30
-DI 22.81
Chandelier Exit (Long, 3 ATRs ) 51.03
Chandelier Exit (Short, 3 ATRs ) 52.15
Upper Bollinger Band 57.72
Lower Bollinger Band 45.70
Percent B (%b) 0.67
BandWidth 23.24
MACD Line 1.60
MACD Signal Line 1.36
MACD Histogram 0.2452
Fundamentals Value
Market Cap 6.58 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -21.23
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.22
Resistance 3 (R3) 56.83 55.28 56.63
Resistance 2 (R2) 55.28 54.39 55.47 56.44
Resistance 1 (R1) 54.50 53.84 54.89 54.89 56.24
Pivot Point 52.95 52.95 53.15 53.14 52.95
Support 1 (S1) 52.17 52.06 52.56 52.56 51.20
Support 2 (S2) 50.62 51.51 50.81 51.00
Support 3 (S3) 49.84 50.62 50.81
Support 4 (S4) 50.23